Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Avicanna Inc T.AVCN

Alternate Symbol(s):  AVCNF

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patients’ needs and enhances the patient's journey.


TSX:AVCN - Post by User

Post by prophetoffactzon Jun 07, 2024 11:43am
48 Views
Post# 36077695

Sheldon Inwentash LOVES AVCN

Sheldon Inwentash LOVES AVCNFrom May 23, 2024 to May 31, 2024 Sheldon Inwentash acquired $88,834 worth of stock to hold 5,567,550. He acquired the shares at prices up to $.2761 - a significant premium to today's price. Paul Fornazzari also acquired $250,662 shares at $.275 on May 28, 2024. The last financing closed in December at $.35 with half a warrant at $.41. 

With the recently reported 51% gross margins last quarter and positive EBITDA for the first time as well confidence in the future that could make AVCN a self-sustaining company as well as recent developments this year it wouldn't take much growth from here to justify the current market cap leaving blue sky upside from there. Sheldon Inwentash and Fonazzari have been buyers of the stock. The markets AVCN addresses are substantial.

Inwentash's IDK recently won a large settlement so lets see if he IDK acquires shares.
<< Previous
Bullboard Posts
Next >>